Nordic Nanovector (OSE: NANO)
Reference is made to the stock exchange notice from Nordic Nanovector
ASA (“Nordic Nanovector” or the “Company”) on 12 February 2015 in
connection with the invitation to today’s investor meeting where the
Company will give an update on the clinical development plan and the
contemplated initial public offering (the “IPO”).
The presentation is now available on www.nordicnanovector.com
under Events & Highlights /IPO and will be presented today at 12:00
hours (CET) by the Company’s management at Hotel Continental,
Stortingsgata 24-26, Oslo, Norway.
ABG Sundal Collier and DNB Markets (a part of DNB Bank ASA) are acting
as Joint Global Coordinators and ABG Sundal Collier, Carnegie and DNB
Markets are acting as Joint Bookrunners in the contemplated IPO.
About Nordic Nanovector
Nordic Nanovector was established in 2009 and has its main office and
laboratories in Oslo, Norway. The Company aspires to become a leading
provider of Antibody-Radionuclide-Conjugate (“ARC”) clinical solutions,
to address major unmet medical needs and to advance cancer care through
its innovative therapy programs and patented technologies. The Company
intends to directly commercialize its product candidates, by creating a
differentiated and specific positioning, investing in cross-specialty
collaboration and medical education. The Company is also committed to
continue developing the ARC pipeline leveraging on its proprietary
nanovector targeting technology. The Company’s lead product candidate,
Betalutin™, is an Antibody-Radionuclide-Conjugate that aims to prolong
the survival and improve the quality of life of patients who suffer from
non-Hodgkin Lymphoma (“NHL”), a life-threatening blood cancer with a
high unmet medical need. The product candidate is currently undergoing a
Phase I/II clinical trial for treatment of relapsed NHL. Further
information about the Company can be found at www.nordicnanovector.com.
IMPORTANT INFORMATION
United States
These materials may not be published, distributed or transmitted in the
United States, Canada, Australia or Japan. These materials do not
constitute an offer of securities for sale or a solicitation of an offer
to purchase securities (the “Shares”) of Nordic Nanovector ASA (the
“Company”) in the United States, Norway or any other jurisdiction. The
Shares of the Company may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S.
Securities Act of 1933, as amended (the “U.S. Securities Act”). The
Shares of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities
Act.
European Economic Area
Any offering of securities will be made by means of a prospectus to be
published that may be obtained from the issuer or selling security
holder, once published, and that will contain detailed information about
the Company and its management, as well as financial statements.
These materials are an advertisement and not a prospectus for the
purposes of Directive 2003/71/EC, as amended (together with any
applicable implementing measures in any Member State, the “Prospectus
Directive”). Investors should not subscribe for any securities referred
to in these materials except on the basis of information contained in
the prospectus. In any EEA Member State other than Norway (from the time
the prospectus has been approved by the Financial Supervisory Authority
of Norway, in its capacity as the competent authority in Norway, and
published in accordance with the Prospectus Directive as implemented in
Norway) that has implemented the Prospectus Directive, this
communication is only addressed to and is only directed at “qualified
investors” in that Member State within the meaning of Article 2(1)(e) of
the Prospectus Directive (“Qualified Investors”), i.e., only to
investors to whom an offer of securities may be made without the
requirement for the Company to publish a prospectus pursuant to Article
3 of the Prospectus Directive in such EEA Member State.
United Kingdom
In the United Kingdom, these materials are only being distributed to and
are only directed at Qualified Investors who (i) are investment
professionals falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the
“Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of
the Order (high net worth companies, unincorporated associations, etc.)
(all such persons together being referred to as “Relevant Persons”).
These materials are directed only at Relevant Persons and must not be
acted on or relied on by persons who are not Relevant Persons. Any
investment or investment activity to which this document relates is
available only to Relevant Persons and will be engaged in only with
Relevant Persons.
About Nordic Nanovector ASA (ticker: NANO on NOTC)
Nordic Nanovector ASA is a privately held company established in 2009.
The company is developing innovative radioimmunotherapeutics to treat
non-Hodgkin Lymphoma (NHL) and other difficult to treat cancers. Nordic
Nanovector intends to commercialise its product candidates through
strategic alliances and partnerships with experienced oncology
businesses and by establishing its own sales and marketing capabilities
in selected markets. The company is based and has offices and
laboratories in Oslo, Norway.
The company’s lead product candidate, Betalutin™, is a
radioimmunotherapeutic that aims to prolong and improve the quality of
life of people who suffer from NHL. Further information can be found at: www.nordicnanovector.com.
About non-Hodgkin Lymphoma
NHL is a life-threatening blood cancer that originates in lymphocytes
and spreads and develops in lymph nodes and other lymphoid tissues. The
incidence rate of NHL worldwide has been dramatically increasing over
the past decades and NHL is today the 10th most commonly diagnosed
cancer and is associated to a high mortality rate. Despite recent
improvements in available therapies, there is still a high unmet medical
need. NHL market is expected to grow by 7% annually for the next four
years to exceed USD 12 billion in 2018 worldwide.
This information was brought to you by Cision http://news.cision.com
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150223005400r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2015